The outlook of companies tied to the drug's past presents a challenging investment picture . While the initial success generated substantial gains, generic alternatives have significantly diminished revenue. Investing in connected pharmaceutical firms now requires a discerning assessment of intellectual property rights , evolving healthcare shifts